Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatmentFully enrolled first cohort is assessing the infectivity of the human challenge inoculumThere are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis across all age groups and geographies with a $60 billion annual economic burdenFDA Fast Track designation granted for CDI-988 underscores the lack of approved ther ...